

September 30, 2026

To, BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers Dalal Street, Mumbai - 400 001 Scrip Code: 544889	To, National Stock Exchange of India Limited Exchange Plaza, 5 th floor, Plot no. C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Symbol: SYMBIOTEC
---	--

Sub: Symbiotec's wholly owned subsidiary Knovea Pharmaceutical enters into strategic commercialization agreement with a leading global pharmaceutical company for Dual Chamber Vial products in the U.S.

Dear Sir/Madam,

Pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached update titled ***“Symbiotec's wholly owned subsidiary Knovea Pharmaceutical enters into strategic commercialization agreement with a leading global pharmaceutical company for Dual Chamber Vial products in the U.S.”***

Further, the details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed as **Annexure A**.

This is for your information and records.

Yours truly,

for **Symbiotec Pharmalab Limited**

SALIL Digitally signed
by SALIL JAIN
Date:
JAIN 2026.09.30
18:31:10 +05'30'

Salil Jain

Company Secretary & Compliance Officer

Membership No. A41610

Encl: Annexure A

Registered Office & Works:

Symbiotec Pharmalab Limited

(Formerly known as Symbiotec Pharmalab Pvt. Ltd.)

385/2, Pigdambar, Rau, Mhow, Indore - 453331, Madhya Pradesh, India

Tel. No.: +91-731-6676405-406 Fax: +91-731-4201222,

Email ID : symbiotec@symbiotec.com, **Website :** www.symbiotec.com

CIN: U24232MP2002PLC015293

Symbiotec's wholly owned subsidiary Knovea Pharmaceutical enters into strategic commercialization agreement with a leading global pharmaceutical company for Dual Chamber Vial products in the U.S.

Indore, September 30, 2026: Knovea Pharmaceutical, a wholly owned subsidiary of Symbiotec Pharmed Limited, today announced a **definitive agreement** with a leading global pharmaceutical company, granting the partner **exclusive rights to commercialise and distribute two Dual Chamber Vial ("DCV")** - based injectable products in the United States.

The agreement marks a decisive step in the commercialization of Knovea's DCV platform. Knovea will lead development, regulatory submissions, manufacturing and supply, while the partner drives commercialization and distribution across the U.S. — bringing established market access and commercial scale to Knovea's platform. The collaboration is structured to deliver milestone payments through development, regulatory approval and commercial launch, alongside profit-sharing from launch onwards.

A DCV keeps a drug, and its diluent separate until they're combined at the point of care — protecting the stability of sensitive formulations while simplifying preparation for healthcare professionals, with fewer handling steps and sterility maintained through administration. Together, the two products address a U.S. market estimated at approximately **US\$288 million**. The innovator is currently the only company with a DCV presentation in this market — underscoring the commercial opportunity for differentiated DCV presentations in injectables.

*Commenting on the agreement, **Mr. Anil Satwani, Managing Director, Symbiotec Pharmed,** said:*

"This agreement is a defining milestone for Knovea. Our sustained investment in building DCV capabilities end-to-end — from product development and regulatory science to commercial-scale sterile manufacturing — is now paying off, with a leading global pharmaceutical company as our exclusive U.S. partner. This opens a powerful commercial pathway in the world's largest pharmaceutical market, and it's only the beginning: we built the DCV platform as a repeatable engine for innovation and expect it to power a growing portfolio of differentiated complex injectables.

This agreement strengthens Knovea's position in complex injectables and opens the door to further collaborations across our differentiated drug-delivery technologies."

Registered Office & Works:

Symbiotec Pharmed Limited

(Formerly known as Symbiotec Pharmed Pvt. Ltd.)

385/2, Pigdambar, Rau, Mhow, Indore - 453331, Madhya Pradesh, India

Tel. No.: +91-731-6676405-406 Fax: +91-731-4201222,

Email ID : symbiotec@symbiotec.com, Website : www.symbiotec.com

CIN: U24232MP2002PLC015293

About Knovea Pharmaceutical Pvt. Ltd. ("Knovea")

Knovea Pharmaceutical Pvt. Ltd., a wholly owned subsidiary of Symbiotec Pharmalab Limited, develops differentiated pharmaceutical products and drug-delivery platforms, with a focus on complex injectables and innovative drug-delivery presentations. Its integrated, end-to-end capabilities span product development, formulation, lyophilization, container-closure development, regulatory support and commercial-scale sterile manufacturing — enabling it to move from concept to commercial supply in a segment with high technical barriers to entry.

About Symbiotec Pharmalab Limited ("Symbiotec")

Symbiotec Pharmalab Limited is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across organic chemistry, biotechnology and complex injectables. Founded in 1995, the Company holds a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients (APIs).

Symbiotec serves over 200 customers across more than 40 countries through three complementary business verticals — APIs, CDMO services and Complex Injectables — supported by four manufacturing facilities in Madhya Pradesh, India, with approvals from USFDA, EU-GMP, WHO-GMP, Japan-PMDA and other leading global regulators.

Disclaimer

Certain statements contained in this document may be statements of future expectations and other forward-looking statements that are based on management's current view and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. None of Symbiotec Pharmalab Limited or any of its affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its content or otherwise arising in connection with this document. This document does not constitute an offer or invitation to purchase or subscribe for any shares and neither it nor any part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.

For further information please contact

Company	Investor Relations Advisors
Symbiotec Pharmalab Limited CIN No: U24232MP2002PLC015293 Email ID: investorrelations@symbiotec.com	Strategic Growth Advisors Pvt Ltd. CIN No: U74140MH2010PTC204285 Sagar Shroff / Prabjeet Singh Tank Email id: sagar.shroff@sgapl.net / prabjeet.singh@sgapl.net Tel No: +91 98205 19303 / +91 81690 49325

Registered Office & Works:

Symbiotec Pharmalab Limited

(Formerly known as Symbiotec Pharmalab Pvt. Ltd.)

385/2, Pigdambar, Rau, Mhow, Indore - 453331, Madhya Pradesh, India

Tel. No.: +91-731-6676405-406 Fax: +91-731-4201222,

Email ID : symbiotec@symbiotec.com, **Website :** www.symbiotec.com

CIN: U24232MP2002PLC015293

Annexure A

Particulars	Remarks
Type of arrangement	Strategic Commercialization Agreement (definitive agreement) entered into by Knovea Pharmaceutical Private Limited, a wholly owned subsidiary of the Company
Name of the entity with whom agreement is signed	A leading global multinational pharmaceutical company [Name cannot be disclosed due to confidentiality obligations]
Area of agreement	The agreement grants the partner exclusive rights to distribute two injectable products in the United States. Both products are built on Knovea's Dual Chamber Vial ("DCV") platform. The agreement marks a decisive step in the commercialization of Knovea's DCV platform. Knovea will lead development, regulatory submissions, manufacturing and supply. The partner will drive commercialization and distribution across the U.S., bringing established market access and commercial scale to Knovea's dual chamber vial platform.
Domestic / International	International (United States)
Share exchange ratio / JV ratio	Not Applicable
Scope of business operation of agreement	Knovea will lead development, regulatory submissions, manufacturing and supply of the products, while the partner will drive commercialization and distribution across the U.S., bringing established market access and commercial scale to Knovea's dual chamber vial platform.
Details of consideration paid / received in agreement	Details cannot be disclosed due to confidentiality obligations.
Significant terms and conditions of agreement in brief	Exclusive rights under a long-term agreement to the partner to distribute two DCV-based injectable products in the United States. Knovea will lead development, regulatory submissions, manufacturing and supply of the products, while the partner will drive commercialization and distribution across the U.S., bringing established market access and commercial scale to Knovea's dual chamber vial platform.

Registered Office & Works:

Symbiotec Pharmed Limited

(Formerly known as Symbiotec Pharmed Pvt. Ltd.)

385/2, Pigdambar, Rau, Mhow, Indore - 453331, Madhya Pradesh, India

Tel. No.: +91-731-6676405-406 Fax: +91-731-4201222,

Email ID : symbiotec@symbiotec.com, **Website :** www.symbiotec.com

CIN: U24232MP2002PLC015293

Particulars	Remarks
Whether the acquisition would fall within related party transactions	Not Applicable
Whether the promoter/ promoter group/ group companies have any interest in the entity being acquired?	Not Applicable
If yes, nature of interest and details thereof	Not Applicable
Whether the same is done at “arm’s length”	Not Applicable
Size of the entity	Cannot be disclosed due to confidentiality obligations
Rationale and benefit expected	The agreement marks a decisive step in the commercialization of Knovea's DCV platform and strengthens Knovea's position in the high-value complex injectables segment. It also opens the door to further partnerships across products that can benefit from Knovea's differentiated drug-delivery and reconstitution technologies.

Registered Office & Works:

Symbiotec Pharmed Limited

(Formerly known as Symbiotec Pharmed Pvt. Ltd.)

385/2, Pigdambar, Rau, Mhow, Indore - 453331, Madhya Pradesh, India

Tel. No.: +91-731-6676405-406 Fax: +91-731-4201222,

Email ID : symbiotec@symbiotec.com, Website : www.symbiotec.com

CIN: U24232MP2002PLC015293